Hybio Pharmaceutical Co., Ltd. (SHE:300199)
16.25
-0.03 (-0.18%)
Jun 27, 2025, 3:04 PM CST
Hybio Pharmaceutical Revenue
Hybio Pharmaceutical had revenue of 309.97M CNY in the quarter ending March 31, 2025, with 106.29% growth. This brings the company's revenue in the last twelve months to 749.91M, up 84.97% year-over-year. In the year 2024, Hybio Pharmaceutical had annual revenue of 590.20M with 36.82% growth.
Revenue (ttm)
749.91M
Revenue Growth
+84.97%
P/S Ratio
19.14
Revenue / Employee
724.55K
Employees
1,035
Market Cap
14.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 590.20M | 158.81M | 36.82% |
Dec 31, 2023 | 431.38M | -272.94M | -38.75% |
Jan 1, 2023 | 704.32M | -31.65M | -4.30% |
Jan 1, 2022 | 735.97M | 14.25M | 1.97% |
Dec 31, 2020 | 721.72M | 107.53M | 17.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Jan 1, 2019 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Sichuan Biokin Pharmaceutical | 5.82B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |